Boryung Biopharama Co. was first established as Boryung Pharmaceutics Inc.
in April 26th, 1991. Our aim was to develop and to sell biological products that were receiving spotlights as the future of pharmaceutical industry.
Initially, Biopharma concentrated in preventive medicinal business such as vaccines, and invested and researched appropriately.
As a result, we developed the first domestic oral vaccines for typhoid.
Our vaccine formula is now patented in 12 countries, including Korea, the United States, Japan, and England which is also contributing to domestic
export.
From the initial stage, Boryung Biopharma has been recognized as an eligible
KGMP manufacturer of all dosage forms of medicine and injections from the Ministry of Health and Welfare therefore we have been manufacturing and
selling superior quality medical supplies. Also, based on our distinguished research ability and technology, we are expanding the R&D field of our products
to vaccines, bio treatments, and diagnostic tests for a wider range of R&D of bio products.
In addition, our excellent marketing strategies made us a major corporation in the domestic preventative medicinal market, and we are going to achieve continuous
growth by pioneering the export market in Southeast Asia, South America, Africa, and more.
In April 26th, 2002, Boryung Pharmaceutics Inc. celebrated our 11th anniversary, and changed the company name to Boryung Biopharma Co.,
and drawing from our experience and accomplishments in preventative medicine, we started to lay a new foundation in the biotechnology industry,
which is a promise for a brighter future.
In July 1st, 2003, we established ¡°Boryung i-Mom Cell¡±, which stores umbilical cord blood (UCB) cells for 15 years using the latest freezing storage. This feat
was possible only from our constant efforts to establish a close cooperative system with our affiliate UCB cell provision bank.
Thanks to the establishment of UCB cell bank, Boryung Biopharma is remodeling itself as the next-generation biological research center,
the concentration of all of Boryung¡¯s technology and know-how that is striving to become a ¡°Lifetime Care Company¡±.
Also, for the purpose of public benefit and trustworthy management, Boryung Biopharma Co., together with Catholic UCB Bank (a bureau within the Catholic
Medical Center), is sponsoring child leukemia patients using part of our business profit. Through our sponsorship, we are respecting the
young lives less fortunate than us, and are accompanying our neighbors
We are a biotechnology specialist, participating in various researches, including stem cell research, cell remedy, tissue engineering, and etc.
in order to contribute to the ever-changing medicine of the future and to the health of our people.
Boryung Biopharma is a leader of the 21st century biotechnology industry and will contribute in the development of the next-generation biotechnology through endless R&D efforts.
|